You just read:

Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Mar 23, 2020, 07:30 ET